PDGFRB and cardiovascular disorder: In conclusion, we report the successful development, GMP-compliant production, and translational validation of [68Ga]Ga-ATH001, a novel Affibody-based PET radiopharmaceutical targeting PDGFRβ for imaging fibrotic remodeling in cardiovascular disease.